Structured diagnostics and therapy of the CUP syndrome;Strukturierte Diagnostik und internistische Therapie des CUP-Syndroms

Radiologe

Volumn 54, Issue 2, 2014, Pages 112-116

  Loffler H ^a   Neben, K ^b   Kramer A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Klinikum Mittelbaden   (Germany)

Author keywords

Carcinoma; Diagnostic focusing; Gene expression profiling; Metastases; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; TUMOR MARKER;

ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL PATHWAY; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; METHODOLOGY; PALLIATIVE THERAPY; SYNDROME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CRITICAL PATHWAYS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; PALLIATIVE CARE; SYNDROME; TUMOR MARKERS, BIOLOGICAL;

EID: 84898540287     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-013-2545-y     Document Type: Article

References (28)

1. Bugat R, Bataillard A, Lesimple T et al (2003) Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89(Suppl 1):S59-S66
2. Culine S, Fabbro M, Ychou M et al (1999) Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy. Ann Oncol 10:569-575
3. Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679-4683
4. Culine S, Lortholary A, Voigt JJ et al (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21:3479-3482
5. Dowell JE, Garrett AM, Shyr Y et al (2001) A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 91:592-597
6. Eagan RT, Therneau TM, Rubin J et al (1987) Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 10:82-85
7. Eu Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr- search/trial/2008-003174-18/DE
8. Falkson CI, Cohen GL (1998) Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55:116-121
9. Fizazi K, Greco FA, Pavlidis N et al (2011) Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi64-vi68
10. Hainsworth JD, Rubin MS, Spigel DR et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol 31:217-223
11. Hainsworth JD, Spigel DR, Farley C et al (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 25:1747- 1752
12. Horlings HM, Van Laar RK, Kerst JM et al (2008) Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26:4435-4441
13. Hübner G, Bokemeyer C (2005) CUP-Syndrom - Tumorerkrankung mit unbekanntem Primärtumor. http://www.dgho-onkopedia.de
14. Kim KW, Krajewski KM, Jagannathan JP et al (2013) Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol 200:484-492
15. Krämer A, Gattenlöhner S, Neben K (2009) CUP-Syndrom: Molekulare Pathogenese und Biologie. Pathologe 30:117-124
16. Massard C, Loriot Y, Fizazi K (2011) Carcinomas of an unknown primary origin - diagnosis and treatment. Nature reviews. Clin Oncol 8:701-710
17. Milliken ST, Tattersall MH, Woods RL et al (1987) Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23:1645-1648
18. Neben K, Hübner G, Folprecht G et al (2008) Metastases in the absence of a primary tumor: advances in the diagnosis and treatment of CUP syndrome. Dtsch Arztebl Int 105:733-740
19. Palmeri S, Lorusso V, Palmeri L et al (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer 107:2898-2905
20. Pentheroudakis G, Greco FA, Pavlidis N (2009) Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev 35:221-227
21. Ramaswamy S, Ross KN, Lander ES et al (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54
22. Rosenfeld N, Aharonov R, Meiri E et al (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462-469
23. Saltz LB (2013) Role of expression profiling in carcinoma of unknown primary remains unknown. J Clin Oncol 31:2513-2514
24. Strojan P, Ferlito A, Langendijk JA et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 35:286- 293
25. Strojan P, Ferlito A, Medina JE et al (2013) Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 35:123-132
26. Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28-e37
27. Varadhachary GR, Karanth S, Qiao W et al (2013) Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol [Epub ahead of print]
28. Varadhachary GR, Talantov D, Raber MN et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442-4448